COVID-19 Convalescent Plasma at Chughtai Lab

COVID-19 Convalescent Plasma at Chughtai Lab

COVID-19 Convalescent Plasma therapy is an advanced investigational treatment and supportive clinical modality that utilizes the antibody-rich plasma of individuals who have fully recovered from a SARS-CoV-2 infection. This therapeutic approach is based on the principles of passive immunization, wherein pre-formed neutralizing antibodies are transferred from a recovered donor to an active patient. These antibodies specifically target the spike protein of the SARS-CoV-2 virus, preventing viral entry into host cells, neutralizing viral particles, and helping the recipient’s immune system clear the infection more effectively. Chughtai Lab, Pakistan’s leading diagnostic network, offers state-of-the-art blood banking, donor screening, and apheresis services to facilitate the safe collection, processing, and distribution of high-titer convalescent plasma across its extensive clinical network in Lahore, Karachi, Islamabad, and other major cities.

The therapeutic efficacy of COVID-19 Convalescent Plasma relies heavily on the concentration of neutralizing antibodies present in the donor’s blood. At Chughtai Lab, donor screening is conducted using highly sensitive chemiluminescent immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) platforms to quantify SARS-CoV-2 IgG antibodies. The collection process is performed using advanced automated apheresis technology. Unlike whole blood donation, apheresis selectively extracts the plasma component while simultaneously returning the red blood cells, white blood cells, and platelets back to the donor. This specialized procedure is safe, highly efficient, and allows for the collection of a larger volume of plasma from a single donor, which can then be aliquoted into therapeutic units to benefit multiple patients in clinical need.

Evaluating the clinical utility of convalescent plasma requires a comprehensive understanding of transfusion medicine and infectious disease dynamics. When administered early in the course of severe disease or to patients with compromised immune systems who cannot produce their own antibodies, convalescent plasma has been shown to reduce viral load, mitigate systemic inflammation, and potentially decrease the duration of hospitalization. Chughtai Lab adheres to the most stringent international guidelines, including those from the World Health Organization (WHO) and the Association for the Advancement of Blood & Biotherapies (AABB), ensuring that every unit of convalescent plasma is thoroughly screened for transfusion-transmitted infections (TTIs) and standardized for antibody potency, thereby maximizing patient safety and therapeutic benefit.

Clinical Procedure: What to Expect

Patient and Donor Preparation

Donor preparation is a critical phase that ensures both donor safety and the high quality of the collected plasma. Potential donors must meet specific clinical criteria before undergoing the apheresis procedure. Donors must have a documented history of SARS-CoV-2 infection confirmed by a molecular PCR test or a highly specific serological assay. They must be fully recovered and completely symptom-free for a minimum of 14 to 28 days prior to donation. Additionally, donors must meet all standard blood donation requirements, including being between 18 and 60 years of age, weighing at least 50 kilograms, and maintaining stable vital signs.

To prepare for the donation process at Chughtai Lab, donors are advised to follow these guidelines:

• Maintain optimal hydration by drinking plenty of water and non-caffeinated fluids for 24 to 48 hours before the procedure.
• Eat a wholesome, low-fat meal a few hours prior to donation to prevent lightheadedness and ensure stable blood glucose levels.
• Avoid consuming alcohol, tobacco, or heavy, fatty foods for at least 24 hours before the collection.
• Get a minimum of 7 to 8 hours of restful sleep the night before the procedure.
• Provide complete medical history documentation, including previous COVID-19 test reports, vaccination records, and details of any ongoing medications.
• Female donors with a history of pregnancy must undergo additional screening for Human Leukocyte Antigen (HLA) antibodies to minimize the risk of Transfusion-Related Acute Lung Injury (TRALI) in the recipient.

During the Procedure

The convalescent plasma collection procedure is conducted in a highly sterile, controlled, and comfortable environment within Chughtai Lab’s specialized blood donor centers. The donor is comfortably positioned in a specialized donor recliner. A highly trained phlebotomist or transfusion medicine technician performs a sterile venipuncture, typically in the antecubital vein of one or both arms, depending on the specific apheresis machine configuration used.

During the automated apheresis process, the donor’s blood is drawn into a sterile, single-use disposable kit installed in the apheresis machine. The machine utilizes centrifugation to separate the blood into its individual components based on density. The liquid plasma portion, containing the valuable SARS-CoV-2 neutralizing antibodies, is directed into a sterile collection bag, while the cellular components—including red blood cells, platelets, and white blood cells—are mixed with a small amount of anticoagulant (citrate) and safely returned to the donor’s circulation. The entire procedure takes approximately 45 to 60 minutes. Throughout this time, clinical staff continuously monitor the donor’s vital signs, including blood pressure, heart rate, and oxygen saturation, ensuring a safe and comfortable experience. Some donors may experience a mild tingling sensation around the mouth due to the citrate anticoagulant, which is easily managed by providing oral calcium supplements.

When is COVID-19 Convalescent Plasma Performed?

Severe COVID-19 Infection with Respiratory Distress

Physicians frequently request COVID-19 Convalescent Plasma for patients hospitalized with severe COVID-19 who exhibit signs of acute respiratory distress, such as tachypnea, hypoxia, or a rapid decline in lung function. In these clinical scenarios, the patient’s immune system is often overwhelmed by viral replication, leading to severe pulmonary inflammation. Administering high-titer convalescent plasma provides immediate passive immunity, helping to neutralize the circulating viral particles, limit further alveolar damage, and support the patient’s respiratory recovery before advanced mechanical ventilation becomes necessary.

Immunocompromised Patients with Active SARS-CoV-2

Patients with compromised immune systems—such as those undergoing active chemotherapy, organ transplant recipients on immunosuppressive regimens, or individuals with primary immunodeficiency disorders—often fail to mount an adequate antibody response to both natural infection and COVID-19 vaccines. For these vulnerable individuals, COVID-19 Convalescent Plasma serves as a vital therapeutic bridge. By supplying external neutralizing antibodies, this therapy assists in clearing the persistent viral infection, preventing prolonged viral shedding, and reducing the risk of severe, life-threatening complications associated with chronic COVID-19 illness.

Early-Stage High-Risk Patients

Clinical evidence suggests that convalescent plasma is highly effective when administered early in the course of the disease, specifically within the first few days of symptom onset. Physicians may recommend this therapy for elderly patients or individuals with significant comorbidities, such as chronic kidney disease, severe cardiovascular disease, or uncontrolled diabetes, who are at an exceptionally high risk of progressing to severe illness. Early intervention with high-titer plasma helps halt viral replication at an early stage, thereby preventing the onset of the hyperinflammatory phase and reducing the likelihood of hospitalization.

Failure of Standard Antiviral Therapies

In cases where patients do not respond adequately to primary antiviral medications, such as remdesivir, or where these medications are contraindicated due to severe renal or hepatic impairment, COVID-19 Convalescent Plasma offers an alternative, targeted therapeutic option. Transfusion medicine specialists and attending physicians collaborate to evaluate the clinical status of the patient, utilizing convalescent plasma to provide direct immunological support and target the viral pathogen directly without placing additional metabolic stress on the patient’s kidneys or liver.

Clinical Trials and Research Protocols

COVID-19 Convalescent Plasma may also be collected and administered under approved clinical trials and research protocols to evaluate its efficacy against emerging SARS-CoV-2 variants. As the virus mutates, Chughtai Lab’s advanced diagnostic capabilities allow researchers to analyze the cross-reactivity and neutralizing capacity of plasma collected from recently recovered or vaccinated individuals. This ongoing scientific evaluation ensures that the therapeutic plasma used in clinical settings remains effective against the circulating viral strains in the community.

What Does COVID-19 Convalescent Plasma Detect and Screen?

Before any convalescent plasma unit can be approved for clinical transfusion, Chughtai Lab performs an extensive panel of laboratory tests on the donor’s blood sample. This comprehensive screening process is designed to verify the therapeutic potency of the plasma and guarantee the absolute safety of the recipient. The following parameters and clinical findings are evaluated during this rigorous screening process:

• SARS-CoV-2 IgG Antibody Titer: Measures the concentration of IgG antibodies directed against the spike protein or receptor-binding domain (RBD) of the virus to ensure high-titer therapeutic efficacy.
• Neutralizing Antibody Levels: Evaluates the functional ability of the donor’s antibodies to inhibit viral entry and replication in vitro.
• ABO Blood Grouping: Identifies the donor’s blood group (A, B, AB, or O) to ensure immunological compatibility with the recipient’s plasma profile.
• Rh Factor Typing: Determines the presence of the D antigen (Rh-positive or Rh-negative) on red blood cells.
• HIV-1 and HIV-2 Screening: Detects antibodies and antigens associated with Human Immunodeficiency Virus to prevent transfusion-transmitted HIV.
• Hepatitis B Surface Antigen (HBsAg): Screens for active Hepatitis B virus infection in the donor.
• Hepatitis C Virus (HCV) Antibodies: Detects exposure to or active infection with the Hepatitis C virus.
• Syphilis Screening (VDRL/RPR): Identifies antibodies against Treponema pallidum to prevent transmission of syphilis.
• Malaria Parasite (MP) Screen: Verifies the absence of Plasmodium species in the donor’s blood.
• Complete Blood Count (CBC): Evaluates overall hematological health, ensuring the donor has adequate cellular counts.
• Hemoglobin (Hb) Level: Confirms that the donor has sufficient oxygen-carrying capacity (minimum 12.5 g/dL) prior to donation.
• Hematocrit (Hct): Measures the volume percentage of red blood cells in the donor’s blood.
• Total Leukocyte Count (TLC): Assesses the donor’s white blood cell count to rule out active bacterial or non-COVID infections.
• Platelet Count: Ensures the donor has a safe level of platelets (minimum 150,000/µL) before undergoing apheresis.
• Total Serum Protein: Verifies that the donor’s protein levels are within normal limits, as plasma extraction removes circulating proteins.
• Serum Albumin: Measures the primary protein responsible for maintaining oncotic pressure in the blood.
• Serum Globulin: Evaluates the baseline immunoglobulin levels in the donor’s blood.
• HLA (Human Leukocyte Antigen) Antibodies: Screened especially in female donors with a history of pregnancy to prevent TRALI in recipients.
• Prothrombin Time (PT): Assesses the extrinsic pathway of coagulation to ensure normal donor clotting function.
• Activated Partial Thromboplastin Time (aPTT): Evaluates the intrinsic coagulation pathway.
• Serum Creatinine: Monitors baseline renal function in the donor.
• Alanine Aminotransferase (ALT): Screens for liver cell injury or inflammation.
• Aspartate Aminotransferase (AST): Evaluates general hepatic and tissue health.
• Bilirubin (Total and Direct): Assesses hepatic excretory function and rules out hemolysis.
• Atypical Red Cell Antibodies: Screens for unexpected antibodies that could cause hemolytic transfusion reactions.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab understands the critical and time-sensitive nature of COVID-19 Convalescent Plasma therapy. The screening of potential donors is prioritized within our advanced laboratory network. Donor screening reports, including SARS-CoV-2 antibody titers and transfusion-transmitted infection (TTI) panels, are typically processed and verified within 12 to 24 hours of sample collection. Once a donor is cleared, the apheresis collection is scheduled immediately, and the processed plasma unit is frozen and prepared for clinical release.

Patients, physicians, and donors can access all diagnostic reports seamlessly through Chughtai Lab’s state-of-the-art digital infrastructure. Reports are available online via the official Chughtai Lab website portal and the dedicated Chughtai Lab mobile application. Additionally, automated SMS notifications with direct download links are sent to registered mobile numbers as soon as the results are verified by our consultant pathologists. For hospitals and clinical facilities, Chughtai Lab provides dedicated coordination services to ensure the rapid, temperature-controlled transport of convalescent plasma units directly to the patient’s bedside, maintaining the cold chain throughout the delivery process.

COVID-19 Convalescent Plasma Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
SARS-CoV-2 IgG Antibody Titer	High Titer (Signal-to-Cutoff Ratio > 9.5 or equivalent)	Low Titer or Non-reactive (Unsuitable for therapeutic use)
ABO and Rh Blood Grouping	Compatible with recipient’s blood group	Incompatible with recipient’s blood group
HIV-1 & HIV-2 Screening	Non-reactive / Negative	Reactive / Positive (Donor deferred, unit discarded)
Hepatitis B Surface Antigen (HBsAg)	Non-reactive / Negative	Reactive / Positive (Donor deferred, unit discarded)
Hepatitis C Virus (HCV) Antibodies	Non-reactive / Negative	Reactive / Positive (Donor deferred, unit discarded)
Syphilis (VDRL/RPR) Screen	Non-reactive / Negative	Reactive / Positive (Donor deferred, unit discarded)
Malaria Parasite (MP) Screen	Not Detected / Negative	Detected / Positive (Donor deferred, unit discarded)
HLA Antibodies (Female Donors)	Negative	Positive (High risk of inducing TRALI in recipient)
Total Serum Protein (Donor)	6.0 to 8.3 g/dL	Decreased (< 6.0 g/dL) or Elevated (> 8.3 g/dL)
Hemoglobin Level (Donor)	≥ 12.5 g/dL	Anemia (< 12.5 g/dL, donor deferred for safety)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for COVID-19 Convalescent Plasma?

• Experienced healthcare professionals, including consultant hematologists, pathologists, and transfusion medicine specialists.
• Patient-focused care ensuring a safe, comfortable, and highly professional donor and recipient experience.
• Quality diagnostic services utilizing state-of-the-art automated apheresis machines and advanced serological testing platforms.
• Professional reporting with rapid turnaround times and stringent quality control protocols for antibody quantification.
• Modern diagnostic approach adhering strictly to international blood banking and transfusion safety standards.
• Comfortable environment with specialized donor lounges designed to make the apheresis process relaxing and stress-free.
• Convenient location network with multiple collection and distribution centers across major cities in Pakistan.
• Commitment to accurate diagnosis and therapeutic safety, ensuring every plasma unit is thoroughly screened for infectious diseases.